-
公开(公告)号：US11827655B2
公开(公告)日：2023-11-28
申请号：US17373354
申请日：2021-07-12
Applicant: University of Massachusetts
Inventor： Gang Han , Ling Huang
CPC classification number: C07F5/022 , A61K31/196 , A61K41/0042 , A61K47/558 , A61K47/6929 , B82Y5/00
Abstract: The invention provides a novel class of materials that possess triplet-triplet annihilation upconversion, compositions and methods of preparation and use thereof. The invention also relates to use of such materials and nanoparticles, for example, in stimulus-responsive, in situ delivery of biologically active agents.
-
公开(公告)号：US10016511B2
公开(公告)日：2018-07-10
申请号：US15431310
申请日：2017-02-13
Applicant: Philochem AG
Inventor： Nikolaus Krall , Willy Decurtins , Dario Neri , Jörg Scheuermann , Moreno Wichert
IPC: A61K31/433 , A61K47/48 , A61K51/08 , A61K38/05
CPC classification number: A61K47/558 , A61K31/433 , A61K31/535 , A61K38/05 , A61K45/06 , A61K47/545 , A61K47/55 , A61K47/65 , A61K51/08 , C07B59/008 , C07B2200/05 , C07K5/0808
Abstract: A binding moiety (B) for Carbonic Anhydrase IX (CAIX), the binding moiety comprising: The binding moiety is univalent, bivalent, or multivalent. A targeted therapeutic agent may comprise the binding moiety. The invention also includes a method for treating a disease expressing elevated levels of CAIX by administering the targeted therapeutic agent.
-
公开(公告)号：US09421274B2
公开(公告)日：2016-08-23
申请号：US14117246
申请日：2012-05-16
Applicant: Marc Stefan Robillard , Hendricus Marie Janssen , Wolter Ten Hoeve , Ronny Mathieu Versteegen
Inventor： Marc Stefan Robillard , Hendricus Marie Janssen , Wolter Ten Hoeve , Ronny Mathieu Versteegen
IPC: C07D257/08 , C07D237/26 , C07C13/263 , C07C33/16 , A61K31/435 , A61K31/502 , A61K31/045 , A61K47/48 , B82Y5/00
CPC classification number: A61K47/6803 , A61K31/435 , A61K31/444 , A61K31/704 , A61K38/05 , A61K39/3955 , A61K39/39558 , A61K47/22 , A61K47/545 , A61K47/555 , A61K47/558 , A61K47/6897 , B82Y5/00 , C07C33/16 , C07D237/26 , C07D257/08 , Y02A50/471
Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.
Abstract translation: 本发明涉及用于治疗剂的前药活化方法，其中使用对彼此具有生物正交反应性的非生物活性化学基团。 本发明还涉及包含至少一种前药和至少一种活化剂的前药盒，其中所述前药包含药物和第一生物正交反应性组（所述触发剂），并且其中所述活化剂包含第二生物正交反应性组 。 本发明还涉及上述方法和试剂盒中使用的靶向治疗剂。 本发明特别涉及抗体 - 药物偶联物和双特异性和三特异性抗体衍生物。
-
4.发明授权Supramolecular metallic complexes exhibiting both DNA binding and photocleavage 有权显示DNA结合和光切割的超分子金属配合物
公开(公告)号：US08148360B2
公开(公告)日：2012-04-03
申请号：US11851689
申请日：2007-09-07
Applicant: Karen J. Brewer , Brenda Winkel
Inventor： Karen J. Brewer , Brenda Winkel
IPC: A61K31/555 , C07F15/00
CPC classification number: A61K31/555 , A61K41/0042 , A61K41/0057 , A61K47/558
Abstract: Supramolecular complexes that target and cleave DNA are provided. The supramolecular complexes include at least one metal-to-ligand charge transfer (MLCT) light absorbing unit, at least one Pt based DNA binding unit, and at least one bridging unit that serves to connect the components. The Pt-based DNA binding unit binds the complex to DNA, and the MLCT unit absorbs light, thereby sensitizing molecular oxygen to produce reactive oxygen species in close proximity to the complex and the bound DNA. The reactive oxygen species cleave the bound DNA.
Abstract translation: 提供靶向和切割DNA的超分子复合物。 超分子复合物包括至少一种金属 - 配体电荷转移（MLCT）光吸收单元，至少一种基于Pt的DNA结合单元和用于连接组分的至少一个桥接单元。 基于Pt的DNA结合单元将复合物与DNA结合，并且MLCT单元吸收光，从而使分子氧致敏以在复合物和结合的DNA附近产生活性氧。 活性氧切割结合的DNA。
-
公开(公告)号：US06555663B1
公开(公告)日：2003-04-29
申请号：US09733809
申请日：2000-12-08
Applicant: Randell Lee Mills
Inventor： Randell Lee Mills
IPC: C07C24500
CPC classification number: C07D213/40 , A61K31/662 , A61K41/0057 , A61K47/54 , A61K47/558 , C07D219/04 , C07D237/28 , C07D405/04 , C07D405/14 , C07D409/12 , C07D493/04 , C07F9/4087 , C07F9/650994 , C07F9/6552 , C07F9/65586 , C07H19/052 , C07H19/20 , C09B23/083
Abstract: A broad class of pharmaceutical agents which react directly with electron carriers or with reactive species produced by electron transport to release a pharmacologically active molecule to effect a therapeutic functional change in the organism by a receptor or nonrecepter mediated action.
Abstract translation: 与电子载体直接反应或通过电子传递产生的反应性物质直接反应以释放药理学活性分子以通过受体或非反应器介导的作用来影响生物体的治疗功能变化的广泛类型的药剂。
-
公开(公告)号：US11957760B2
公开(公告)日：2024-04-16
申请号：US18183328
申请日：2023-03-14
Applicant: Elucida Oncology, Inc.
Inventor： Kai Ma , Aranapakam M. Venkatesan , Feng Chen , Fei Wu , Melik Ziya Türker , Thomas Courtney Gardinier, II , Geno J. Germano, Jr. , Gregory Paul Adams , Francis Y. F. Lee
IPC: A61K9/00 , A61K31/4192 , A61K47/10 , A61K47/54 , A61K47/55 , A61K47/60 , A61K47/69 , A61K49/00 , A61P35/00
CPC classification number: A61K47/552 , A61K31/4192 , A61K47/10 , A61K47/545 , A61K47/551 , A61K47/558 , A61K47/60 , A61K47/6923 , A61K47/6929 , A61K49/0032 , A61K49/0093 , A61P35/00
Abstract: The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.
-
公开(公告)号：US20240091371A1
公开(公告)日：2024-03-21
申请号：US18497645
申请日：2023-10-30
Applicant: Tagworks Pharmaceuticals B.V.
Inventor： Marc Stefan ROBILLARD , Hendricus Marie JANSSEN , Wolter TEN HOEVE , Ronny Mathieu VERSTEEGEN , Raffaella ROSSIN
IPC: A61K47/68 , A61K31/435 , A61K31/444 , A61K31/704 , A61K38/05 , A61K39/395 , A61K47/22 , A61K47/54 , B82Y5/00 , C07C33/16 , C07D237/26 , C07D257/08
CPC classification number: A61K47/6803 , A61K31/435 , A61K31/444 , A61K31/704 , A61K38/05 , A61K39/3955 , A61K39/39558 , A61K47/22 , A61K47/545 , A61K47/555 , A61K47/558 , A61K47/6897 , B82Y5/00 , C07C33/16 , C07D237/26 , C07D257/08 , Y02A50/30
Abstract: The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.
-
公开(公告)号：US11878059B2
公开(公告)日：2024-01-23
申请号：US16618227
申请日：2018-05-31
Applicant: UNIVERSITY OF ULSTER
Inventor： John Callan , Anthony Mchale , Sukanta Kamila , Keiran Logan
IPC: A61K47/69 , A61K41/00 , A61K47/54 , A61K47/55 , A61P35/00 , A61K31/337 , A61K31/7048 , A61K31/7068 , A61K47/24
CPC classification number: A61K41/0033 , A61K31/337 , A61K31/7048 , A61K31/7068 , A61K41/0042 , A61K47/24 , A61K47/542 , A61K47/549 , A61K47/55 , A61K47/557 , A61K47/558 , A61K47/6925 , A61P35/00
Abstract: The invention relates to microbubble complexes for use in methods of sonodynamic therapy which comprise a microbubble attached to or otherwise associated with one or more linking groups, each linking group being bound to at least one sonosensitising agent and at least one chemotherapeutic agent. It further relates to the microbubble complexes themselves and to pharmaceutical compositions which contain them. The invention is particularly suitable for the treatment of deep-sited tumors, in particular pancreatic cancer.
-
公开(公告)号：US11744897B2
公开(公告)日：2023-09-05
申请号：US17867025
申请日：2022-07-18
Applicant: Elucida Oncology, Inc.
Inventor： Kai Ma , Aranapakam M. Venkatesan , Feng Chen , Fei Wu , Melik Ziya Türker , Thomas Courtney Gardinier, II , Geno J. Germano, Jr. , Gregory Paul Adams , Francis Y. F. Lee
CPC classification number: A61K47/552 , A61K47/545 , A61K47/551 , A61K47/558 , A61K47/60 , A61K47/6923 , A61K47/6929 , A61K49/0032 , A61K49/0093 , A61P35/00
Abstract: The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.
-
公开(公告)号：US20230263899A1
公开(公告)日：2023-08-24
申请号：US18183328
申请日：2023-03-14
Applicant: Elucida Oncology, Inc.
Inventor： Kai MA , Aranapakam M. VENKATESAN , Feng CHEN , Fei WU , Melik Ziya TÜRKER , Thomas Courtney GARDINIER, II , Geno J. GERMANO, Jr. , Gregory Paul ADAMS , Francis Y.F. LEE
CPC classification number: A61K47/552 , A61K47/558 , A61K47/545 , A61K47/551 , A61K47/6923 , A61K47/60 , A61P35/00 , A61K47/6929 , A61K49/0032 , A61K49/0093
Abstract: The disclosure relates to nanoparticle drug conjugates (NDC) that comprise ultrasmall nanoparticles, folate receptor (FR) targeting ligands, and linker-drug conjugates, and methods of making and using them to treat cancer.
